Research analysts covering Advanced Biomed.
Recent press releases and 8-K filings for ADVB.
Advanced Biomed Inc. Announces A+PerfusC™ Platform Launch
ADVB
Product Launch
New Projects/Investments
- Advanced Biomed Inc. (Nasdaq: ADVB) announced the launch of its A+PerfusC™ system, an integrated perfusion 3D cell culture platform for precision medicine and drug discovery.
- The A+PerfusC™ platform is a compact, all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro, supporting up to 12 days of continuous, hands-free culture.
- Potential applications for the system include personalized oncology research, in vitro drug screening, regenerative medicine, organoid studies, and stem cell research.
- The system has passed internal testing and validation, with its design finalized, and the company is currently advancing its mass-production development for commercialization.
Sep 19, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more